290 related articles for article (PubMed ID: 23990115)
1. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
3. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
[TBL] [Abstract][Full Text] [Related]
5. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
10. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
[TBL] [Abstract][Full Text] [Related]
11. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
12. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.
Geuns-Meyer S; Cee VJ; Deak HL; Du B; Hodous BL; Nguyen HN; Olivieri PR; Schenkel LB; Vaida KR; Andrews P; Bak A; Be X; Beltran PJ; Bush TL; Chaves MK; Chung G; Dai Y; Eden P; Hanestad K; Huang L; Lin MH; Tang J; Ziegler B; Radinsky R; Kendall R; Patel VF; Payton M
J Med Chem; 2015 Jul; 58(13):5189-207. PubMed ID: 25970324
[TBL] [Abstract][Full Text] [Related]
14. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A; Clark A; Assayag F; Chateau-Joubert S; Poupon MF; Servely JL; Fontaine JJ; Liu X; Spooner E; Goodstal S; de Cremoux P; Bièche I; Decaudin D; Marangoni E
Mol Cancer Ther; 2012 Dec; 11(12):2693-703. PubMed ID: 23012245
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
19. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Bello E; Taraboletti G; Colella G; Zucchetti M; Forestieri D; Licandro SA; Berndt A; Richter P; D'Incalci M; Cavalletti E; Giavazzi R; Camboni G; Damia G
Mol Cancer Ther; 2013 Feb; 12(2):131-40. PubMed ID: 23270924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
